Completion lymphadenectomy may not increase in-transit disease in malignant melanoma
- PMID: 15564269
- PMCID: PMC534491
- DOI: 10.1136/bmj.329.7477.1288-c
Completion lymphadenectomy may not increase in-transit disease in malignant melanoma
Comment on
-
The argument against sentinel node biopsy for malignant melanoma.BMJ. 2000 Jul 1;321(7252):3-4. doi: 10.1136/bmj.321.7252.3. BMJ. 2000. PMID: 10875809 Free PMC article. No abstract available.
-
Sentinel lymph node biopsy: not yet standard of care for melanoma.BMJ. 2004 Jul 17;329(7458):170; author reply 170-1. doi: 10.1136/bmj.329.7458.170. BMJ. 2004. PMID: 15258079 Free PMC article. No abstract available.
References
-
- Powell AM, Calonje E, Acland K, Healy C, Doherty M, Grunewald T, et al. Pattern of clinical recurrence in patients with malignant melanoma and negative sentinel node biopsies. Br J Dermatol 2004;151(suppl 68): 82-3.
-
- Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002;147: 62-70. - PubMed
-
- Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003;29: 241-52. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical